Gender, Age, Disease Severity, Body Mass Index and Diabetes May Not Affect Response to Subcutaneous Tanezumab in Patients with Osteoarthritis after 16 Weeks of Treatment. A Subgroup Analysis of Placebo‐controlled Trials